NASDAQ:ACAD - ACADIA Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$18.93 +0.30 (+1.61 %)
(As of 11/18/2018 11:38 AM ET)
Previous Close$18.93
Today's Range$18.1221 - $19.24
52-Week Range$12.77 - $32.99
Volume1.74 million shs
Average Volume3.00 million shs
Market Capitalization$2.37 billion
P/E RatioN/A
Dividend YieldN/A
Beta3.35
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Receive ACAD News and Ratings via Email

Sign-up to receive the latest news and ratings for ACAD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ACAD
Previous Symbol
CUSIPN/A
Phone858-558-2871

Debt

Debt-to-Equity RatioN/A
Current Ratio6.08
Quick Ratio5.98

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$124.90 million
Price / Sales18.96
Cash FlowN/A
Price / CashN/A
Book Value$1.79 per share
Price / Book10.58

Profitability

EPS (Most Recent Fiscal Year)($2.36)
Net Income$-289,400,000.00
Net Margins-119.62%
Return on Equity-88.18%
Return on Assets-75.50%

Miscellaneous

Employees425
Outstanding Shares125,070,000
Market Cap$2.37 billion
OptionableOptionable

ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) posted its earnings results on Tuesday, November, 6th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.58) by $0.08. The biopharmaceutical company earned $58.31 million during the quarter, compared to analysts' expectations of $56.31 million. ACADIA Pharmaceuticals had a negative net margin of 119.62% and a negative return on equity of 88.18%. The company's revenue was up 63.9% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.53) earnings per share. View ACADIA Pharmaceuticals' Earnings History.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for ACADIA Pharmaceuticals.

What price target have analysts set for ACAD?

9 Wall Street analysts have issued twelve-month price targets for ACADIA Pharmaceuticals' stock. Their forecasts range from $17.00 to $60.00. On average, they anticipate ACADIA Pharmaceuticals' stock price to reach $32.6667 in the next year. This suggests a possible upside of 72.6% from the stock's current price. View Analyst Price Targets for ACADIA Pharmaceuticals.

What is the consensus analysts' recommendation for ACADIA Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last year. There are currently 3 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ACADIA Pharmaceuticals.

What are Wall Street analysts saying about ACADIA Pharmaceuticals stock?

Here are some recent quotes from research analysts about ACADIA Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "Our $60 PT is based on an equally weighted composite of: (a) $69/share, as a 35x multiple of taxed and diluted FY22 GAAP EPS of $4.09 discounted back to and (b) an NPV of $50/share (discount rate 10%, growth rate 2.5%)." (11/1/2018)
  • 2. Cantor Fitzgerald analysts commented, ". We reiterate our Overweight rating and raise our 12-month price target to $27 from $25. In August 2018, ACADIA announced a licensing agreement with Neuren Pharmaceuticals (ASX: Rett syndrome. Although this program has yet to take center stage, we believe it is an underappreciated asset that could diversify the pipeline/business strategy over the next 12 months. We recently had an opportunity to meet with Neuren to discuss the history/future of Trofi’." (10/15/2018)
  • 3. According to Zacks Investment Research, "Acadia Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs for the treatment of central nervous system disorders. Their three clinical programs are ACP-103 for treatment-induced dysfunction in Parkinson's disease, and ACP-104 and ACP-103, both for the treatment of schizophrenia. " (10/8/2018)

Has ACADIA Pharmaceuticals been receiving favorable news coverage?

News coverage about ACAD stock has trended very positive recently, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ACADIA Pharmaceuticals earned a news sentiment score of 3.2 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term.

Are investors shorting ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals saw a decrease in short interest during the month of October. As of October 31st, there was short interest totalling 15,937,478 shares, a decrease of 13.6% from the October 15th total of 18,444,733 shares. Based on an average trading volume of 3,272,148 shares, the days-to-cover ratio is presently 4.9 days. Currently, 12.8% of the company's stock are sold short. View ACADIA Pharmaceuticals' Current Options Chain.

Who are some of ACADIA Pharmaceuticals' key competitors?

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the folowing people:
  • Mr. Stephen R. Davis, Pres, CEO & Director (Age 57)
  • Mr. Todd S. Young, Exec. VP & CFO (Age 46)
  • Dr. Srdjan R. Stankovic, Exec. VP and Head of R&D (Age 61)
  • Mr. Michael J. Yang, Exec. VP & Chief Commercial Officer (Age 56)
  • Mr. Bob Mischler, Sr. VP of Strategy & Technology Operations

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Baker BROS. Advisors LP (22.74%), FMR LLC (15.00%), BlackRock Inc. (7.83%), First Trust Advisors LP (4.70%), Janus Henderson Group PLC (2.51%) and Deutsche Bank AG (1.48%). Company insiders that own ACADIA Pharmaceuticals stock include Bros Advisors Lp Baker, Daniel B Soland, Glenn Baity, Laura Brege and Terrence O Moore. View Institutional Ownership Trends for ACADIA Pharmaceuticals.

Which major investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including Canada Pension Plan Investment Board, Janus Henderson Group PLC, Deutsche Bank AG, Wells Fargo & Company MN, Creative Planning, Renaissance Technologies LLC, Credit Suisse AG and Daiwa Securities Group Inc.. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Glenn Baity and Laura Brege. View Insider Buying and Selling for ACADIA Pharmaceuticals.

Which major investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was acquired by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Baker BROS. Advisors LP, Peregrine Capital Management LLC, Fuller & Thaler Asset Management Inc., Fosun International Ltd, Opaleye Management Inc., Macquarie Group Ltd. and Moody Aldrich Partners LLC. Company insiders that have bought ACADIA Pharmaceuticals stock in the last two years include Bros Advisors Lp Baker and Daniel B Soland. View Insider Buying and Selling for ACADIA Pharmaceuticals.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $18.93.

How big of a company is ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals has a market capitalization of $2.37 billion and generates $124.90 million in revenue each year. The biopharmaceutical company earns $-289,400,000.00 in net income (profit) each year or ($2.36) on an earnings per share basis. ACADIA Pharmaceuticals employs 425 workers across the globe.

What is ACADIA Pharmaceuticals' official website?

The official website for ACADIA Pharmaceuticals is http://www.acadia-pharm.com.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 858-558-2871 or via email at [email protected]


MarketBeat Community Rating for ACADIA Pharmaceuticals (NASDAQ ACAD)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  601 (Vote Outperform)
Underperform Votes:  301 (Vote Underperform)
Total Votes:  902
MarketBeat's community ratings are surveys of what our community members think about ACADIA Pharmaceuticals and other stocks. Vote "Outperform" if you believe ACAD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACAD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel